Peptidase (DPPIV): A Comprehensive Reference
1. Identity, Nomenclature, and Classification
Dipeptidyl Peptidase IV (DPP-IV, also known as CD26) is an enzyme and immune cell surface antigen that removes N-terminal dipeptides when the penultimate residue is proline or alanine, thereby altering the activity of many hormones, chemokines, and neuropeptides. Alternative names include Dipeptidyl peptidase-4, DPP-4, CD26, and Adenosine deaminase complexing protein 2 (ADCP2). It is classified as a serine exopeptidase and a type II transmembrane glycoprotein that forms active homodimers.
Dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5) is a serine enzyme with an apparent mass of 250 kDa, consisting of two identical subunits with an apparent mass of 100 kDa each. DPP-4 is expressed on epithelial and endothelial surfaces (kidney, intestine, liver, lung), on activated T lymphocytes, and exists as a proteolytically shed soluble form (sDPP-4) in plasma.
In the context of dietary supplementation, the term Peptidase (DPPIV) refers specifically to an exogenous, orally administered proline-specific peptidase preparation — typically of microbial/fungal origin — formulated to replicate the digestive activity of the endogenous enzyme. The endogenous DPP-4 (also known as CD26) is a membrane-anchored and soluble serine protease that inactivates regulatory peptides such as GLP-1 and GIP, modulates immune signaling, and is the pharmacologic target of the DPP-4 inhibitor class of antidiabetic drugs (gliptins).
The catalytic activity is defined under Enzyme Commission number EC 3.4.14.5. DPP-4 (also known as CD26) was first described in 1966 by Hopsu-Havu and Glenner by its enzymatic activity in rat liver. This multifunctional type II transmembrane glycoprotein is a 110-kDa member of the prolyl oligopeptidase family, which functions as a cell surface serine protease, selectively cleaving dipeptides from peptides and proteins containing proline or alanine in the N-terminal penultimate position. The CD26 antigen was linked to DPP-4 activity in the 1980s and the gene was cloned in the 1990s.
2. Natural Sources and Production of Supplemental DPPIV
The koji mold Aspergillus oryzae secretes a prolyl dipeptidyl peptidase (DPPIV) when the fungus is cultivated in a medium containing wheat gluten as the sole nitrogen and carbon source. The DPPIV gene from an A. oryzae library has been cloned and sequenced. The gene encodes an 87.2-kDa polypeptide chain which is secreted into the medium as a 95-kDa glycoprotein.
Food-grade proteolytic enzyme preparations produced by Aspergillus oryzae fermentation under current GMP exhibit high dipeptidyl-aminopeptidase activity, in contrast to other fungal proteinase preparations. These preparations also have high proteinase activity, and with this proteolytic combination system, it is possible to hydrolyze various proteins to high levels.
A specific strain of Aspergillus oryzae (AO-1), isolated from a fermented food in Japan, has been reported to produce DPP-IV-related compounds. The yellow koji mold A. oryzae has been traditionally used in Japan in fermented foods such as soy sauce, miso, and sake, and therefore its safety for human consumption has long been verified. The United States Food and Drug Administration (FDA) classified this fungus as Generally Recognized as Safe (GRAS).
Beyond Aspergillus oryzae, DPPIV activity has been identified and characterized from other microbial species. β-Casomorphin (BCM) from milk casein, gluteomorphin (GM) from wheat gluten, and soymorphin (SM) from the soybean β-conglycinin β-subunit are natural substrates of DPPIV. DPPIV from Lactococcus lactis spp. lactis has been purified and characterized by mass spectrometry, demonstrating that the enzyme occurs across multiple microbial kingdoms.
To ensure the safety of food-grade enzymes, the Joint Food and Agricultural Organization/World Health Organization Expert Committee on Food Additives requires that food enzymes derived from fungal sources do not contain detectable amounts of aflatoxin B1, ochratoxin, sterigmatocystin, T-2 toxin, or zearalenone.
3. Common Forms and Preparations
In commercial dietary supplements, DPPIV activity is typically delivered as part of a broader digestive enzyme blend in oral capsule or tablet form. Supplement labels quantify activity in DPPIV Units (DPPIV U), a standardized assay based on hydrolysis of the substrate Gly-Pro-p-nitroanilide. The assay used to detect dipeptidyl-aminopeptidase IV activity (DPP IV) utilizes GLY-PRO p-nitroanilide, a hydrolysate substrate. Dipeptidyl-aminopeptidase cleaves the p-nitroanilidic bond, liberating p-nitroaniline, which in turn linearly absorbs light at 405 nm wavelength.
The pH optimum of Aspergillus oryzae-derived DPPIV preparations is 7.5, with a stability range of 5.0 to 8.0. This physiological pH range is compatible with activity in the small intestinal lumen, making the enzyme suitable for oral supplementation targeting small intestinal digestion.
Commercial products frequently combine DPPIV with other protease enzymes to achieve broad-spectrum protein digestion. Commercially available enzyme blends typically contain special protease enzymes derived from a unique blend of A. oryzae and B. licheniformis to provide complete digestion of all proteins, with additional enzymes derived from aspergillus, papaya and pineapple to support digestion of sugars, fats, carbohydrates, starches, and complex polysaccharides.
A well-known trademarked ingredient is BioCore® DPP IV, supplied by Deerland Probiotics & Enzymes, Inc., which is incorporated into various branded digestive enzyme products. DPP IV (Dipeptidyl peptidase IV) is described as a unique enzyme with specific activity against the characteristic proline bonds found in cereal grain proteins, often combined with proteases and amylases that address other protein and carbohydrate components that commonly co-occur in these foods.
4. Historical and Traditional Context
DPP-IV was identified and studied in the mid-20th century during advances in protein chemistry and immunology. Unlike botanical-based digestive enzymes such as bromelain (from pineapple) or papain (from papaya), DPPIV as an isolated supplement has no documented use in ancient or traditional herbal medicine systems; it is a discovery of modern biochemistry.
The patented production of A. oryzae Taka-diastase, a neutral α-amylase, as a medicine in 1894 marked the beginning of modern enzyme biotechnology, establishing the broader precedent for fungal enzyme use in health applications. Digestive aid enzymes were historically "most often fungal in origin," and preparations from Aspergillus oryzae and Aspergillus niger were most commonly used due to their high content of amylase and protease.
The application of DPP-IV supplements in natural health emerged in the early 2000s, particularly through autism research and gluten-sensitive populations. It became a focus in biomedical approaches to autism, where children with suspected "leaky gut" or caseomorphin/gluteomorphin sensitivity were observed to respond positively to DPP-IV enzyme support. These empirical observations preceded rigorous clinical trials and gave rise to a growing market for DPPIV-containing digestive enzyme supplements.
5. Biochemistry, Key Constituents, and Mechanisms of Action
5.1 Structural Characteristics
Dipeptidyl-peptidase IV/CD26 (DPP IV) is a cell-surface protease belonging to the prolyloligopeptidase family. It selectively removes the N-terminal dipeptide from peptides with proline or alanine in the second position. The widespread expression of DPP-IV means that it can easily access and inactivate a wide variety of biological regulatory peptides, including GIP, GLP-1, growth hormone, peptide YY and neuropeptide Y. DPP-IV has a relatively strict substrate specificity and principally cleaves proline (Xaa–Pro; where Xaa is any amino acid) or alanine (Xaa–Ala) containing dipeptides from the N-terminal of a polypeptide.
5.2 Digestive and Proteolytic Role
Exopeptidases are key for completing protein digestion, including proline-rich peptides, and are mostly produced by enterocytes of the intestinal brush border membrane. In coeliac disease, chronic inflammatory damage disrupts this process. DPPIV acts as an exopeptidase that progressively cleaves dipeptides from the N-terminus of proline-rich protein fragments — precisely the type of peptides that resist degradation by the major pancreatic endoproteases (trypsin, chymotrypsin, elastase).
Brush border membrane vesicles from adult rat intestines have been used to show that proline-glutamine-rich peptides are exceptionally resistant to enzymatic processing, and that dipeptidyl peptidase IV and dipeptidyl carboxypeptidase are the rate-limiting enzymes in their digestion.
Food-derived opioid peptides that are released from proteins by digestion, fermentation, or food production processes can lead to several health problems. These opioids are generally resistant to hydrolysis by proteases, except the dipeptidyl peptidase IV (DPPIV) enzyme, because of their proline amino acid content.
5.3 Endocrine and Metabolic Role
Dipeptidyl peptidase IV (DPP-IV) is a ubiquitous proteolytic enzyme involved in the degradation of incretin hormones such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones assist in diverse biological processes, such as reducing postprandial plasma glucose levels, enhancing insulin synthesis, preserving pancreatic beta-cell function, facilitating peripheral glucose uptake and elimination, moderating gastric emptying rate, bolstering glucose metabolism, and promoting satiety.
DPP-IV is responsible for the metabolic cleavage of certain endogenous peptides (GLP-1 (7-36), glucagon) in vivo and has demonstrated proteolytic activity against a variety of other peptides (GHRH, NPY, GLP-2, VIP) in vitro. DPP-IV is thought to regulate the activity of multiple physiologically important peptides, including, but not limited to, GLP1, GIP, GLP2, GRP, vasoactive intestinal peptide, peptide histidine methionine, PYY, substance P, beta-casomorphine, NPY, PACAP38, prolactin, and other regulatory molecules.
5.4 Immune Function
Apart from its catalytic activity, DPP IV interacts with several proteins, for instance, adenosine deaminase, the HIV gp120 protein, fibronectin, collagen, the chemokine receptor CXCR4, and the tyrosine phosphatase CD45. DPP IV is expressed on a specific set of T lymphocytes, where it is up-regulated after activation. It is also expressed in a variety of tissues, primarily on endothelial and epithelial cells.
CD26/DPP4 has been implicated in the modulation of T-cell activation and proliferation, and CD26/DPP4-positive T cells are characterized by remarkable anti-tumor properties, rendering them interesting candidates for T cell-based immunotherapies. Current data point to an important role for CD26/DPP4 in maintaining lymphocyte composition and function, T cell activation and co-stimulation, memory T cell generation, and thymic emigration patterns during immune-senescence.
DPPIV is involved in immune response and nonspecific inflammatory processes, and its decreased activity is generally associated with impaired immune status.
5.5 Opioid Peptide Metabolism
DPP-IV is the main enzyme responsible for the hydrolysis of certain dipeptides into free amino acids. It is a cell surface enzyme present in various types of cells, such as endothelial cells and brush border in the intestinal mucosa, and is present in soluble form in the bloodstream. DPP-IV is considered the main enzyme responsible for the cleavage of β-casomorphin-7 (BCM-7), as it selectively removes the dipeptide containing proline (Pro61) in N-terminal peptides.
Gluteomorphins and caseomorphins are bioactive peptides formed during incomplete digestion of gluten and casein, respectively, which studies have shown can interact with opioid receptors in the brain. Further research indicates these bioactive peptides can adversely affect the central nervous system, and abnormal levels have been linked to neurological disorders including ADD/ADHD, autism and schizophrenia.
6. Scientific Evidence by Area of Use
6.1 Digestive Support and Protein Hydrolysis
The most biochemically well-established role for exogenous DPPIV supplementation is the facilitation of protein digestion, particularly of proline-rich proteins such as gluten and casein.
Inflammatory damage to the intestinal epithelium in coeliac disease is associated with reduced brush border exopeptidase activity, and this enzyme loss is likely to exacerbate gluten peptide accumulation.
Dipeptidyl peptidase IV and dipeptidyl carboxypeptidase I have been identified as the rate-limiting enzymes in the digestive breakdown of immunodominant gluten peptides, as estimated from the residual peptide structure and confirmed by exogenous peptidase supplementation. A similar conclusion also emerged from analogous studies with brush-border membrane from a human intestinal biopsy.
A 2025 review in a peer-reviewed journal examined the design of exopeptidase enzyme therapies for celiac disease. One novel enzyme therapy approach using a combination of two tandem-acting exopeptidases (AMYNOPEP) to complement the intrinsic enzymatic activity of intestinal brush border enterocytes was evaluated for its effects on degradation of the immunodominant gluten 33-mer in vitro and in vivo. In a cross-over clinical study, healthy volunteers with no gastrointestinal disorders were given stable isotope-labelled 33-mer peptides in the presence of varying peptide substrates and caloric loads, with and without AMYNOPEP. However, this study involved an exopeptidase combination therapy rather than a standalone DPPIV supplement, and results specifically for DPPIV alone in clinical human trials remain limited.
In vitro experiments have shown that purified DPPIV enzyme added to standard food-derived opioid peptides hydrolyzed BCM (33.42% for 2 mM), soymorphin (83.81% for 2 mM), and gluteomorphin (45.73% for 2 mM). These are in vitro data only and do not directly confirm equivalent hydrolysis efficiency in a live human gastrointestinal environment.
More complete digestion of dietary proteins with supplemental enzymes including proline-specific peptidases may be beneficial for conditions associated with incomplete protein breakdown. This claim, however, is largely supported by in vitro and mechanistic evidence rather than robust randomized controlled trials in humans.
6.2 Celiac Disease and Gluten Sensitivity
Dipeptidylpeptidase IV (DPP IV) activity has been shown cytochemically to decrease significantly in enterocytes of children suffering from coeliac disease. This decrease is due to a halving of the time available for enterocytes to express DPP IV in their brush-border membranes during development.
In animal models differing in their response to gliadin feeding, the activities of DPP IV and lactase were decreased in rat pups, nu/nu BALB/c mice and piglets compared to albumin-fed controls. DPP IV activity was mostly affected in the ileum of rats and piglets fed with gliadin starting at birth.
The principal toxic components of wheat gluten are a family of Pro- and Gln-rich proteins called gliadins, which are resistant to degradation in the gastrointestinal tract and contain several T-cell-stimulatory epitopes. Peroral peptidase supplementation has been proposed as a therapeutic strategy. This approach is considered to aid complete digestion of immunostimulatory peptides by involvement of bacterial prolyl endopeptidases which have broad tolerance for proline-containing peptides.
DPP4 cleaves peptides that are over-represented in the gluten epitopes that bind to HLA haplotype DR3-DQ2; although a direct causal link has yet to be established, the activity of intestinal DPP4 is decreased in the acute phase of celiac disease.
Evidence quality assessment: While the mechanistic rationale for DPPIV supplementation in gluten sensitivity is well-supported by biochemical and animal data, large, randomized, placebo-controlled trials evaluating standalone oral DPPIV supplement preparations in celiac disease or non-celiac gluten sensitivity have not been identified in the peer-reviewed literature reviewed for this article. The evidence remains preclinical and mechanistic.
6.3 Autism Spectrum Disorder and the Opioid Excess Hypothesis
Opioid peptides released during digestion of dietary proteins such as casein were suggested to contribute to autism development, leading to the announcement of the opioid excess hypothesis of autism. This hypothesis examines the role of enzyme proline dipeptidyl peptidase-4 (DPPIV; EC 3.4.14.5) and its exogenous substrate, β-casomorphin-7 (BCM7), in autism etiology.
One of the most biologically active milk-derived peptides is β-casomorphin-7 (BCM7; YPFPGPI), released from bovine β-casein. BCM7 has the ability to permeate the intestinal barrier and may induce biological effects through the μ-opioid receptors (MORs) in the immune and nervous systems. BCMs were found to have an inflammatory effect on the gastrointestinal system and may contribute to the etiology of food allergy.
Deficiency of DPPIV and/or its lower enzymatic activity have been suggested as possible causes for the increased level of opioids in patients with autism. A pilot study measuring plasma DPPIV levels found that plasma DPP IV levels were lower in autistic subjects than in control group subjects.
One observational study determined that the concentration of BCM7 in serum was significantly, 1.6-fold, higher in the ASD group than in controls (p < 0.0001). The concentration of DPPIV was found to also be significantly higher in serum from ASD children compared to the control group (p < 0.01), while no significant difference in enzymatic activity of serum DPPIV between the two study groups was noted.
Despite findings suggesting that milk-derived opioid peptides and DPPIV are potentially factors in determining the pathogenesis of autism, conducted studies are still limited and require further investigation. For dietary supplements to be promising for reducing the adverse effects of food-derived opioids, this must be supported by in vivo studies of DPPIV use in the human body.
Evidence quality assessment: The evidence linking low DPPIV activity to ASD is inconsistent and preliminary. While some researchers have concluded that autistic patients have lower levels of plasma DPPIV than controls, other investigators did not find any defects in DPPIV in the blood of autistic children. No rigorous randomized controlled trials of DPPIV supplementation in ASD with behavioral outcome measures have been identified in the peer-reviewed sources reviewed for this article. The opioid excess hypothesis itself remains a subject of scientific debate.
6.4 Food-Derived DPP-IV Inhibitory Peptides and Metabolic Health
A parallel and distinct body of research concerns naturally occurring food-derived peptides that inhibit DPPIV activity (as opposed to the supplemental use of the DPPIV enzyme itself). Over ten dipeptidyl peptidase IV (DPP-IV) inhibitory drugs have been developed and marketed around the world in the past decade. However, owing to the reported adverse effects of synthetic DPP-IV inhibitors, attempts have been made to find DPP-IV inhibitors from natural sources. Food-derived components, such as protein hydrolysates (peptides), have been suggested as potential DPP-IV inhibitors which can help manage blood glucose levels.
DPP-IV inhibitors have been discovered in foods, herbal preparations, natural sources, and traditional Chinese medicines, including phenolic compounds from blueberry–blackberry wine blends, alkaloids from seed extract of Castanospermum australe, and procyanidins from grape seed, all of which have shown DPP-IV inhibitory activity.
In silico analysis of chickpea proteins identified 290 and 275 DPP-IV inhibitory peptides encrypted in the whole legumin and provicilin protein sequences. After in silico enzymatic hydrolysis, a total of 191 legumin and 190 provicilin DPP-IV inhibitory peptides were released. This area of research is largely in vitro and in silico; translation to clinically meaningful blood glucose reductions in humans requires further confirmation.
6.5 Bone Metabolism
Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type 2 diabetes mellitus. Emerging effects of DPP-4 on bone metabolism include an inverse relationship between DPP-4 activity levels and bone mineral density, along with an increased risk of fractures.
The influence of DPP-4 on bone metabolism occurs through the entero-endocrine-osseous axis, involving gastrointestinal substrates for DPP-4, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptides 1 (GLP-1) and 2 (GLP-2). Studies suggest that supraphysiological doses of exogenous GLP-2 have a significant inhibitory effect on bone resorption. GIP stands out for its role in bone formation.
Evidence quality assessment: The bone metabolism effects of DPP-4 activity modulation are primarily studied in the context of pharmaceutical DPP-4 inhibitor drugs, not dietary enzyme supplements. Direct evidence that oral DPPIV enzyme supplementation influences bone metabolism in humans is not currently established.
7. Body Systems and Health Areas Associated With DPPIV
- Gastrointestinal system: Primary site of supplemental DPPIV action; the enzyme is active at the intestinal brush border, facilitating digestion of proline-rich peptides that otherwise resist complete enzymatic breakdown.
- Immune system: CD26/DPP4 is expressed on several immune cell types including T and NK cells, dendritic cells, and activated B cells, playing a role in immune surveillance and regulation.
- Endocrine/metabolic system: GLP-1 and GIP play a crucial role in maintaining glucose homeostasis by stimulating insulin secretion from pancreatic β-cells and inhibiting the release of glucagon. DPP4 is a highly specific serine protease that selectively cleaves these hormones, resulting in their inactivation. DPP4 thus plays a pivotal role in degrading GLP-1 and GIP, hindering their ability to exert hypoglycemic effects.
- Central nervous system (indirect): Decreased activity of gastrointestinal DPPIV has been suggested as a cause of inadequate digestion of caseins and glutens, with the resulting exorphins demonstrating pro-inflammatory properties. "Leakiness" of both the intestinal and blood-brain barriers, observed in some autistic patients, could result in easier access of neuroactive peptides and food-derived antigens to the CNS, which could have pro-inflammatory and neurobehavioral consequences.
- Musculoskeletal system: DPP-4 inhibitors have the potential to decrease bone resorption, increase bone formation, and reduce the incidence of osteoporosis and fractures, though this is studied pharmacologically rather than through enzyme supplementation.
8. Dosage Forms and Reported Dosages
Oral DPPIV enzyme supplements are available in capsule and tablet forms. Enzyme activity is measured in DPPIV Units (DPPIV U), which reflect the enzyme's capacity to cleave the substrate Gly-Pro-p-nitroanilide under standardized conditions. One commercially available enzyme blend has been formulated to include 500 DPPIV units per dose.
The pH optimum for A. oryzae-derived DPPIV is 7.5, with a stability range of 5.0 to 8.0, suggesting the enzyme is active in the small intestinal environment but may have reduced activity in the highly acidic stomach. Enteric-coated formulations or encapsulation strategies are sometimes used in enzyme supplements to reduce gastric degradation, though specific clinical comparisons of coated versus uncoated DPPIV preparations are not well established in the peer-reviewed literature.
No standardized, consensus therapeutic dosage for DPPIV supplements has been established through randomized clinical trials. The dosages cited in commercial products (typically in the range of 500 DPPIV Units per serving, taken with meals) are based on manufacturer specifications rather than dose-finding clinical studies. Researchers who have evaluated digestive enzyme therapy for celiac disease have used combinations of exopeptidases, but specific DPPIV-unit dosing information from controlled trials is not currently available in the published literature reviewed for this article.
9. Safety Considerations and Potential Interactions
9.1 General Safety of Microbial Enzyme Preparations
The yellow koji mold A. oryzae has been traditionally used in Japan in fermented foods such as soy sauce, miso, and sake, and its safety for human consumption has long been verified. The United States Food and Drug Administration (FDA) classified this fungus as Generally Recognized as Safe (GRAS).
A notable inhalation risk applies to powdered enzyme preparations: repeated inhalation of enzyme aerosol or dust may cause allergic-type reactions in sensitized individuals. This risk is primarily occupational (handling bulk enzyme powders) rather than a concern for consumers taking encapsulated supplements.
9.2 Celiac Disease — Critical Limitation
Supplemental DPPIV enzyme preparations are not approved treatments for celiac disease and should not be used as a substitute for a strict gluten-free diet. A relatively large fragment of gliadin that is resistant to digestive enzyme degradation has been identified, and current in vitro evidence suggests that DPPIV alone is insufficient to fully degrade all immunogenic gliadin peptides. The complete destruction of immunodominant epitopes requires a combination of exopeptidase and endopeptidase activities.
9.3 Important Conceptual Distinction: Supplement vs. Pharmaceutical DPP-4 Inhibitors
In the pharmaceutical world, DPP-IV inhibitors (not to be confused with enzyme supplements) are a class of drugs used in type 2 diabetes management. These drugs inhibit the breakdown of incretin hormones, helping to regulate blood sugar by increasing insulin secretion and decreasing glucagon levels. While this is a different mechanism from the supplemental enzyme's role in digestion, it highlights DPP-IV's broader metabolic importance. A dietary DPPIV enzyme supplement adds the enzyme to the gut lumen to aid digestion; it does not inhibit the endogenous enzyme. The two categories should not be confused.
Synthetic DPP-IV inhibitor drugs are reported to have some adverse effects, including gastrointestinal adverse effects, allergic reactions, skin-related side effects, and musculoskeletal disorders. These adverse effects are properties of pharmaceutical inhibitor drugs and are not directly applicable to oral digestive enzyme supplements.
9.4 Immune Modulation Considerations
CD26/DPP4 plays an integral role in the immune system, particularly in T cell activation. Inhibition of DPP4 might therefore represent a double-edged sword — apart from the metabolic benefit, the associated immunological effects of long-term DPP4 inhibition on regulatory processes such as T cell homeostasis and maturation are a concern. This consideration applies primarily to pharmaceutical DPP-4 inhibitors at systemic drug concentrations, rather than to oral enzyme supplements acting locally in the gut lumen. Nevertheless, the broad systemic roles of the endogenous DPP-4/CD26 enzyme system underscore the biological complexity of this target.
9.5 Cancer Biology — Contextual Awareness
DPP-4 is characterized as a T-cell differentiation antigen (CD26) and plays a multifunctional role through its enzymatic and nonenzymatic action. DPP-4 cleaves many substances, not only incretin hormones; DPP-4 inhibitors potentially increase many growth factors and chemokines that may induce cancer progression. DPP-4 has many pivotal roles in immune function, inflammation, and antioxidative response. The pleiotropic effects of DPP-4 inhibitors would not always be favorable, especially in cancer-bearing patients. Again, these concerns are specific to pharmacological inhibition of systemic DPP-4, not to oral digestive enzyme supplementation.
9.6 Evidence Gaps
As of the sources reviewed for this article, comprehensive safety data from randomized controlled trials specifically evaluating oral DPPIV enzyme supplements — including their potential to affect systemic DPPIV activity, incretin metabolism, or immune function — are not available. Most safety assumptions for supplemental DPPIV preparations are based on the GRAS status of Aspergillus oryzae as a fermentation source and the general safety record of orally administered digestive enzyme preparations.
10. Summary of Evidence Quality
- Well-established (biochemistry/preclinical): DPPIV's enzymatic specificity for proline-containing peptides; its role as rate-limiting enzyme in gluten/casein digestion; its endogenous physiological roles in incretin metabolism and immune signaling.
- Supported by observational and in vitro data: Reduced intestinal DPPIV activity in celiac disease; reduced plasma DPPIV in some autism cohorts; in vitro hydrolysis of food-derived opioid peptides by supplemental DPPIV.
- Preliminary / mechanistic only: Clinical benefit of oral DPPIV enzyme supplementation for celiac disease, gluten sensitivity, ASD, or metabolic health — robust randomized controlled trials are lacking.
- Not established for enzyme supplementation: Bone effects, systemic immune effects, or direct glucose-lowering from dietary DPPIV preparations (distinct from pharmaceutical inhibitors).
References
Go back